POS0705 BILAG-2004 INDEX ACTIVE DISEASE PREDICTS DEVELOPMENT OF DAMAGE

Background: BILAG-2004 Index (BILAG-2004) has undergone construct and criterion validity is used to assess disease activity in SLE. However, its predictive yet be established. Objectives: This study was determine if according of development damage an inception cohort. Methods: a prospective multi-centre longitudinal the UK cohort SLE patients (recruited within 12 months achieving 1997 ACR revised criteria for SLE). Data were collected on (BILAG-2004 BILAG2004-Pregnancy during pregnancy), SLICC/ACR DI (SDI), cumulative drug exposure death at every visit. Information cardiovascular risk factors (hypertension, diabetes mellitus, hypercholesterolaemia smoking status) antiphospholipid syndrome status also collected. ran from 1st January 2005 31st December 2017. Longitudinal analysis using Poisson regression with random effects model predictors new damage. Death not included due small numbers. Results: 273 recruited (91.2% female, 59.3% Caucasian, 17.2% African/Caribbean, South Asian) mean age recruitment 38.5 years (SD 14.8). 97.8% had no (2.2% SDI score 1). Median follow-up 73.4 (range: 1.8, 153.8) total 1767 patient-years. Prevalence were: hypertension 23.1%, 35.5%, mellitus 5.5%, smoker or ex-smoker 44% 7%. There 13 deaths 114 items occurred follow-up. 6674 assessments score: 293 Grade A 95 (92.4% only 1 system grade A, range: - 4) 1704 B 239 (78.7% B, 5). Univariate showed that gender, factors, most (except hydroxychloroquine, glucocorticoids, mycophenolate cyclophosphamide) associated (they multivariate analysis). Table summarises analysis. Similar results obtained when variable changed Number Systems per assessment (RR 2.04 95% CI: 1.05, 3.94). Analysis systems tally persistent minimal protective 0.74 0.57, 0.95). Cumulative since against 0.99 CI 0.99, 0.99) but last Variable Risk Ratio (95% CI) New Damage Ethnicity Afro-Caribbean 1.21 (0.68, 2.17) Asian 1.81 (0.97, 3.36) Others 2.37 8.20) Age diagnosis 1.06 (1.04, 1.08 ) Prior 0.69 (0.44, 1.08) Constitutional unreliable estimate low numbers Mucocutaneous 1.80 3.14 Neuropsychiatric 4.68 (1.68, 13.05 Musculoskeletal 0.76 (0.33, 1.73) Cardiorespiratory 0.35 (0.05, 2.59) GIT Ophthalmic Renal 2.08 (0.99, 4.40) Haematological 4.37 (1.15, 16.65 Hydroxychloroquine visit (per g (0.98, Prednisolone 100mg 1.01 (1.00, 1.02 Cyclophosphamide g) 1.42 (0.94, 2.14) Conclusion: Active (Grade B) index patients. References: [1]Yee C. S., et al. The – novel way representing scores longitudinally. Rheumatology (Oxford) 2012; 51[11]: 2099-2105. Acknowledgements: Versus Arthritis Vifor Pharma Disclosure Interests: Chee-Seng Yee Consultant of: Bristol Myers Squibb, ImmuPharma, Grant/research support from: Pharma, Vernon Farewell: None declared, Mohammed Akil: Peter Lanyon: Christopher John Edwards Glaxo Smith Kline, Roche, David Isenberg: Anisur Rahman: Lee-Suan Teh: Sofia Tosounidou: Robert Stevens: Ahtiveer Prabu: Bridget Griffiths: Neil McHugh: Ian N. Bruce: Yasmeen Ahmad: Munther Khamashta: Caroline Gordon Speakers bureau: UCB, Center Disease Control, Astra-Zeneca, MGP, Sanofi UCB